行情

HRTX

HRTX

Heron Inc
NASDAQ

实时行情|Nasdaq Last Sale

13.92
+0.37
+2.73%
交易中 14:58 04/08 EDT
开盘
13.84
昨收
13.55
最高
13.93
最低
13.41
成交量
68.10万
成交额
--
52周最高
26.81
52周最低
9.60
市值
12.58亿
市盈率(TTM)
-5.5580
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测HRTX价格均价为39.78,最高价位65.00,最低价为28.00。

EPS

HRTX 新闻

更多
  • Do Hedge Funds Love Heron Therapeutics Inc (HRTX)?
  • Insider Monkey · 22小时前
  • Despite Lacking Profits Heron Therapeutics (NASDAQ:HRTX) Seems To Be On Top Of Its Debt
  • Simply Wall St. · 3天前
  • FDA accepts Innocoll application for post-surgical pain implant
  • seekingalpha · 03/26 22:10
  • Key events next week - healthcare
  • Seeking Alpha - Article · 03/20 15:23

所属板块

生物技术和医学研究
+3.08%
制药与医学研究
+3.02%

热门股票

代码
价格
涨跌幅

HRTX 简况

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
展开

微牛提供Heron Therapeutics Inc(NASDAQ-HRTX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的HRTX股票新闻,以帮助您做出投资决策。